EVIDENCE WATCH
A review and assessment of recent clinical trial data

Adjuvant and neoadjuvant chemotherapy
PHASE III STUDY OF DOXORUBICIN-CYCLOPHOSPHAMIDE FOLLOWED BY PACLITAXEL OR DOCETAXEL GIVEN EVERY 3 WEEKS OR WEEKLY IN PATIENTS WITH AXILLARY NODE-POSITIVE OR HIGH-RISK NODE-NEGATIVE BREAST CANCER: RESULTS OF NORTH AMERICAN BREAST CANCER INTERGROUP TRIAL E1199. ABSTRACT 48.

FIVE YEAR FOLLOW-UP OF INT C9741: DOSE-DENSE (DD) CHEMOTHERAPY (CRX) IS SAFE AND EFFECTIVE. ABSTRACT 41.

Follicular lymphoma
CHIMERIC ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB; MABTHERA) IN REMISSION INDUCTION AND MAINTENANCE TREATMENT OF RELAPSED / RESISTANT FOLLICULAR NON-HODGKIN’S LYMPHOMA: FINAL ANALYSIS OF A PHASE III RANDOMIZED INTERGROUP CLINICAL TRIAL. ABSTRACT 353.

MAINTENANCE RITUXIMAB AFTER CVP RESULTS IN SUPERIOR CLINICAL OUTCOME IN ADVANCED FOLLICULAR LYMPHOMA (FL): RESULTS OF THE E1496 PHASE III TRIAL FROM THE EASTERN COOPERATIVE ONCOLOGY GROUP AND THE CANCER AND LEUKEMIA GROUP B. ABSTRACT 349.

 

To view the clinical trial data of the above topics click here (pdf format)
Back to Top of Page 

 

 
 
 
Oncology Exchange provides overviews of important clinical trial data presented at the 28TH San Antonio Breast Cancer Symposium, held December 8–11 in San Antonio, Texas, and at the 47TH Annual Meeting of the American Society of Hematology, held December 10–13 in Atlanta, Georgia. Leading Canadian experts offer commentary and clinical interpretations. Reporting on both conferences will continue in the next issue of Oncology Exchange.
 
© Parkhurst Publishing Privacy Statement
Legal Terms of Use
 Site created by Spin Design (514) 995-4398